Impact of Hormonal Contraceptives on HPV Dynamics in Adolescent Girls and Young Women: a Prospective Cohort Sub-Study in South Africa

Ramla F. Tanko[1,2], Ongeziwe Taku[1], Zizipho Z. A. Mbulawa[1,3,4], Keletso Phohlo[1], Iyaloo Konstantinus[1,5], Christina Balle[1], Tanya Pidwell[1], Anna-Ursula Happel[1,6], Katherine Gill,[1,7] Linda-Gail Bekker[1,7], Heather B. Jaspan[1,8], Anna-Lise Williamson[8], Jo-Ann S. Passmore[1,9,10]

[1]Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, South Africa; [2]The Medical Research Centre, Institute of Medical Research and Medicinal Plant Studies (IMPM), Ministry of Scientific Research and Innovation, Yaoundé, Cameroon; [3]Department of Laboratory Medicine and Pathology, Walter Sisulu University, Mthatha, Eastern Cape, South Africa; [4]National Health Laboratory Service, Mthatha, South Africa; [5]Namibia Institute of Pathology, Windhoek, Namibia; [6]Division of Immunology, University of Cape Town, South Africa; [7]Desmond Tutu Health Foundation, Cape Town, South Africa; [8]Seattle Children's Research Institute, Seattle, USA; [9]Department of Science and Technology-National Research Foundation CAPRISA Centre of Excellence in HIV Prevention, Cape Town, South Africa; [10]National Health Laboratory Service, Cape Town, South Africa

Correspondence: Professor Jo-Ann Passmore, Institute of Infectious Disease and Molecular Medicine, Division of Medical Virology, University of Cape Town, Werner Beit North, Level 3 South Pavilion N3.2; Anzio Road, Observatory, 7925, Cape Town, South Africa.

Phone: +27 21 650 7963, e-mail: jo-ann.passmore@uct.ac.za

Keywords: Human papillomavirus, cervical HPV, adolescent girls, persistence, hormonal contraceptives, Net-EN, COCPs, CCVR

Words: 2668

Figures: 2

Tables: 2

Supplementary Figures: 2

Running title: Hormonal contraceptives and HPV dynamics in AGYW

ABSTRACT (249 words)

Objectives: Human papillomavirus (HPV) is causally associated with cervical cancer, with adolescent girls and young women (AGYW) in sub-Saharan Africa bearing a high burden. Hormonal contraceptives may influence HPV acquisition, persistence, and clearance, but evidence remains inconclusive. Here, we evaluated the impact of hormonal contraceptive methods on HPV prevalence and dynamics in AGYW.

Methods: Ninety-eight AGYW (15–19 years) were randomized to receive norethisterone enanthate (Net-EN), combined oral contraceptive pills (COCPs), or the etonorgestrel/ethinyl estradiol combined contraceptive vaginal ring (CCVR). Cervical samples were collected at baseline and 16 weeks for HPV genotyping. HPV prevalence, acquisition, persistence, and clearance were compared across contraceptive methods.

Results: Baseline HPV prevalence was high (93/98; 94.9%) and did not differ between arms. At 16 weeks, HPV prevalence remained high (87/97; 89.5%), with no significant differences in overall HPV prevalence or genotype distribution by method. Longitudinal analyses of paired samples (n=87) showed no statistically significant differences in HPV acquisition, persistence, or clearance across methods. However, descriptively distinct patterns of high-risk HPV dynamics were observed, with greater proportions of high-risk HPV clearance in the Net-EN and COCP arms and a higher proportion of newly acquired or persistent high-risk HPV genotypes among CCVR users.

Conclusions: Hormonal contraceptive methods were not associated with significant differences in overall HPV prevalence or genotype distribution in this cohort of AGYW. Nonetheless, non-significant differences in HPV acquisition, persistence, and clearance were observed over 16-weeks, underscoring the need for larger and longer-term studies to clarify the impact of hormonal contraception on HPV dynamics.

INTRODUCTION

Human papillomavirus (HPV) is one of the most prevalent sexually transmitted infections (STIs) affecting the human genital tract (1). Of the over 200 identified HPV types, only certain mucosal types are classified as high-risk (HR) due to their strong association with cancers (2,3). HPV-16 and HPV-18 are responsible for ~70% of cervical cancer cases globally and contribute significantly to other HPV-related malignancies, including anal, vaginal, vulvar, penile, and oropharyngeal cancers. Cervical cancer remains particularly widespread in sub-Saharan Africa, where incidence rates surpass those of other regions (4,5).

Risk of HPV infection is likely to be influenced by a combination of environmental, biological, and behavioral factors. Biologically, an impaired immune system, such as in individuals with HIV/AIDS, increases susceptibility to persistent HPV infections, while genetic predispositions (6) and co-infections with other STIs further elevate the risk (7). Key behavioral factors include early sexual debut, unprotected sex, multiple sexual partners, smoking, and prolonged use of hormonal contraceptives—all of which are associated with heightened risks of infection and cervical cancer (8). Understanding these complex factors is essential for developing targeted prevention and intervention strategies.

Observational studies have suggested that hormonal contraceptives may influence HPV dynamics (9-11). For instance, combined oral contraceptive pills (COCPs) have been associated with reduced HPV clearance, though other studies found no effect except with extended exposure. Meta-analyses suggest prolonged hormonal contraceptive use is linked to invasive cervical cancer (12,13), yet evidence on its relationship with HPV detection remains inconclusive.

Adolescent girls and young women (AGYW) in South Africa carry a high burden of HPV infection (14). Many of these AGYW are within their first year of sexual debut, with a median of one lifetime

sexual partner (15), underscoring the alarming overlap between high HPV prevalence and vaccine coverage gaps.

Hormonal contraceptives have been shown to induce relatively rapid changes in the genital mucosal environment, including alterations in inflammation, epithelial barrier function, and microbial composition (16-18), all of which may influence susceptibility to STIs such as HPV (9-10). However, data examining the relationship between different hormonal contraceptive methods and HPV infection—particularly for the etonorgestrel/ethinyl estradiol combined contraceptive vaginal ring (CCVR)—remain limited, especially among AGYW in high-burden African settings.

This study therefore aimed to evaluate HPV prevalence, genotype distribution, and HPV dynamics (acquisition, persistence, and clearance) over the initial 16-week randomized exposure period among South African AGYW randomized to receive norethisterone enanthate (Net-EN), the CCVR, or COCPs.

METHODS AND MATERIALS

Description of study cohort

Between September 2015 and July 2017, 130 AGYW between the ages of 15 and 19 were recruited from the Desmond Tutu Health Foundation Youth Centre in Cape Town into an open-label, randomized crossover study evaluating the acceptability, feasibility, and adherence to contraceptive choices (uChoose study; clinicaltrials.gov number NCT02404038) (15). Eligible participants were HIV-seronegative, sexually active, not pregnant, had no symptomatic STIs that required antibiotic treatment in the 40 days prior to enrolment, and agreed not to use non-study vaginal products (including intravaginal douches, washes, lubricants, spermicides, herbal or traditional intravaginal products, or over-the-counter vaginal medications) for the duration of the study. The parent uChoose study was originally designed to enroll AGYW initiating hormonal contraception for the first time.

However, because sexual debut commonly occurred before 15 years of age in the study communities, many otherwise eligible participants had already initiated contraception. Eligibility criteria were therefore amended to include AGYW who were already using a hormonal contraceptive, provided they were willing to switch to one of the randomized study methods. Following screening (baseline visit), eligible AGYW were randomized 1:1:1 to receive one of three hormonal contraceptive methods for 16 weeks: injectable norethisterone enanthate (Net-EN; 200 mg intramuscularly every 8 weeks), combined oral contraceptive pills (COCPs; Triphasil® or Nordette®, containing ethinyl estradiol [30–35 μg] and levonorgestrel [50–150 μg] per tablet, taken daily), or the combined contraceptive vaginal ring (CCVR; NuvaRing®, releasing etonogestrel 120 μg/day and ethinyl estradiol 15 μg/day) . Although the parent uChoose study employed a randomized crossover design, the present HPV sub-study was restricted to the first randomized contraceptive exposure period only (baseline to 16 weeks), prior to any crossover. HPV outcomes were therefore analysed as a parallel-group comparison based on initial randomization. The 16-week interval was selected to capture early biological effects of hormonal contraceptive exposure on the cervicovaginal mucosa, rather than longer-term clinical endpoints. Because all participants were using hormonal contraceptives as part of the parent randomized trial, no non-hormonal control group was included; comparisons therefore reflect relative differences between hormonal contraceptive methods rather than effects versus no hormonal exposure. AGYW who were <18 years provided written assent, and informed consent was obtained from their parents or legal guardians. AGYW who were ≥18 years old provided written informed consent. Ethical approval for the study was obtained from the University of Cape Town Human Research Ethics Committees (UCT HREC 801/2014).

Testing for bacterial STIs and Bacterial vaginosis (BV)

At the time of sampling, vulvovaginal swabs were screened for *Chlamydia trachomatis, Neisseria gonorrhoea, Trichomonas vaginalis, and Mycoplasma genitalium* using a validated in house real-

time multiplex PCR assay performed at the NHLS STI Surveillance Centre, as previously described (19). BV was diagnosed using Nugent scoring of Gram-stained vaginal smears, with Nugent Scores of 7-10 indicating a BV positive result (20). Vaginal pH levels were measured using color-fixed indicator strips (Macherey-Nagel, Düren, Germany). Participants who tested positive for STIs and/or BV received treatment according to the South African HIV Clinicians Society guideline for the management of STIs (21), and treatment was provided irrespective of study arm.

HPV genotyping

HPV genotyping was performed at baseline and after 16 weeks on extracted DNA (MagNA Pure Compact Nucleic Acid Isolation Kit; Roche), from endocervical swabs collected during the speculum examination, using the HPV Direct Flow Chip test (Master Diagnóstica, Granada, Spain), according to the manufacturers' instructions. STI testing and cervical HPV sampling were performed at the same study visit, prior to receipt of any antimicrobial treatment. The Direct Flow Chip detects 36 different HPV genotypes, including the 12 HR types based on recent IARC-aligned causal attribution analyses of HPV genotypes associated with invasive cervical cancer (3) (HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, and -59). The assay also detects an additional 5 HPV types previously considered HR (26, 53, 66, 73, 82; according to the kit manufacturers), HPV-68, as well as 18 low-risk (LR) types (6, 11, 40, 42, 43, 44, 54, 55, 61, 62, 67, 69, 70, 71, 72, 81, 84, 89). For the purposes of HR-HPV analysis, HR-HPV types as defined by the IARC-aligned causal attribution framework (3); genotypes previously classified as HR but no longer included are shown separately. For the purposes of LR-HPV analysis, the manufacturers definition of LR-HPV types was used. A sample was considered HPV positive when at least one HPV genotype was detected. Specimens testing positive for 2 or more HPV genotypes were considered to 16 weeks in AGYW who did not have that HPV type present at baseline. HPV persistence was defined as having the same HPV genotype

detected at both baseline and 16 weeks, in the same participant. HPV clearance was defined as women testing negative for any HPV genotype at 16 weeks that was present at baseline.

Statistical analyses

As HPV outcomes were evaluated only during the first randomized exposure period, crossover effects and within-participant comparisons across contraceptive methods were not assessed in this sub-study. Cross-sectional analyses of HPV prevalence and genotype distribution at baseline and week 16 used all available samples at each time point, whereas analyses of HPV clearance, persistence, and acquisition were restricted to participants with paired samples. Fisher's exact test and descriptive statistics were used to compare differences between hormonal contraceptive arms for categorical variables. Within-arm changes in HPV outcomes between baseline and 16 weeks were assessed using McNemar's test for paired binary data. Continuous variables were described using median and interquartile range (IQR) and compared using the Kruskal Wallis-test. $P<0.05$ was considered statistically significant. Statistical analyses were performed using GraphPad Prism version 9 (GraphPad Software, USA).

RESULTS

Of the 130 AGYW enrolled into the parent uChoose study, endocervical samples were available for HPV genotyping from 98 women at baseline (98/130; 74.5%) and 95 at 16 weeks (95/130; 73.1%; **Supplementary Figure 1**). This included 36 matched sample pairs (baseline and 16 weeks) from AGYW randomized to receive Net-EN, 25 matched samples from AGYW randomized to receive COCPs, and 26 who were randomized to receive the CCVR. All HPV analyses reflect outcomes during the initial 16-week randomized contraceptive exposure period, before participants crossed over to an alternative method. Cross-sectional analyses of HPV prevalence and genotype distribution

at baseline and at 16 weeks used all available samples at each time point. In contrast, analyses of HPV clearance, persistence, and acquisition were restricted to participants with paired baseline and 16-week samples only.

Demographics, genital infections, sexual risk behaviors, prior hormonal contraceptive use, and endogenous hormone levels did not significantly differ among hormonal contraceptive methods at baseline (**Table 1**). Consistent with the amended eligibility criteria of the parent study (15), most participants reported prior hormonal contraceptive use at enrolment. Baseline HPV prevalence was high (93/98; 94.9%) and did not differ between randomization arms (Figure 1; Table 2), with most AGYW having multiple HPV infections (79/98; 80.5%). No statistically significant differences were observed in either between-arm comparisons or within-arm changes over time. The prevalence of any high-risk HPV (HR-HPV) at baseline was 78.6% (77/98), with HPV-31 and HPV-39 being the most frequently detected HR types (each 18/98; 18.4%), while HPV-16 and HPV-18 were detected in 6/98 (6.1%) and 14/98 (14.2%) participants, respectively (**Supplementary Figure 2**). Overall, HPV genotypes targeted by currently available bivalent and nonavalent vaccines accounted for a minority of detected HR-HPV types in this cohort.

At 16 weeks, the HPV prevalence remained high (85/95; 89.5%). Overall HPV prevalence and HR-HPV prevalence did not differ significantly by study arm (**Figure 1 and Table 2**). AGYW randomized to the Net-EN arm had an HPV prevalence (any) of 86.1% (31/36) at 16 weeks compared to 97.2% (35/36) at baseline (p=0.07), those using COCPs had the same HPV prevalence at baseline and 16 weeks (both 88.0% [22/25]; p=1.0), and those randomized to the CCVR group had an HPV prevalence of 92.3% at 16 weeks compared to 96.2% at baseline (24/26 vs 25/26; p=0.5). For HR-HPV types, 66.7% of women randomized to Net-EN had a HR-HPV type at 16 weeks compared to 80.6% at baseline (24/36 vs 29/36, p=0.2), 56.0% of those using COCPs had HR-HPV infections at

week 16 compared to 72.0% at baseline (14/25 vs 18/25; p=0.6), and those randomized to the CCVR group had an HPV prevalence of 76.9% at 16 weeks compared to 80.8% at baseline (20/26 vs 21/26; p=0.5).

Longitudinal analyses of HR-HPV genotype distribution showed no significant differences between the hormonal contraceptive arms, whether considering women who cleared infections (by type), had persistent infections (same type), or acquired new HPV genotype infections (by type; **Figure 2B**). These longitudinal analyses were restricted to participants with paired baseline and 16-week HPV samples. However, the combined prevalence of newly acquired and persistent HR-HPV genotypes was numerically higher among AGYW randomized to the CCVR compared with those using Net-EN or COCPs, although these differences did not reach statistical significance. In contrast, AGYW randomized to Net-EN showed a numerically higher combined prevalence of cleared HR-HPV genotypes over the study period compared with the other two contraceptive arms.

DISCUSSION

This sub-study of a randomized controlled trial (15) compared HPV prevalence and genotype distribution among AGYW randomized to three common hormonal contraceptives: CCVR, the injectable Net-EN, and COCPs. Our results revealed high HPV prevalence across all contraceptive methods at baseline, with no significant differences in overall prevalence or genotype distribution linked to any specific contraceptive arm after 16 weeks of use. Longitudinal analyses showed some variations in HR-HPV dynamics over the 16-week study period, although these were not significant. AGYW using Net-EN tended to clear more HR-HPV types, whereas those using the CCVR tended to acquire more HR-HPV infections that persisted compared to those in the other contraceptive arms.

The high HPV prevalence observed in this cohort aligns with other studies indicating that AGYW are at significant risk of acquiring HPV infections shortly after sexual debut (22,23). This rapid increase, often within the first six months of sexual activity, is influenced by factors such as sexual behaviors, the number of sexual partners, and immune response (23). In this study, an early average age of sexual debut and additional risk factors, such as inconsistent condom use, multiple sexual partners, and high rates of other STIs, likely contributed to the high HPV rates at baseline. Although South Africa introduced the bivalent HPV vaccine prior to the study period (24), the predominance of non-vaccine HR-HPV genotypes in this cohort highlights ongoing gaps in population-level protection.

We have previously shown that hormonal contraceptives exert distinct effects on the mucosal environment of the female genital tract, as evidenced by changes in microbial composition (18), inflammatory markers (16), and gene expression (17). In this cohort, AGYW randomized to Net-EN exhibited higher vaginal microbial diversity and proinflammatory taxa compared to those using COCPs, who had associated with increased lactobacilli and reduced genital inflammation (16, 18). CCVR use, however, was linked to elevated transcriptional networks involving interleukin (IL)-6, IL-1, and NF-κB, suggesting increased genital tract inflammation, alongside reduced epithelial barrier integrity (17). As altered vaginal microbiota and chronic inflammation have all previously been associated with HPV infection and carcinogenesis (25, 26), this may explain our observation that AGYW using the CCVR might be more likely to acquire and retain HR-HPV infections compared to other contraceptive users.

Several studies from sub-Saharan Africa and other population-based cohorts have examined the relationship between intrauterine device (IUD) use and cervical HPV outcomes, with most reporting no increased risk of HPV acquisition among IUD users (27, 28). Studies have additionally suggested higher rates of HPV clearance, particularly among copper IUD users (29), whereas findings for

levonorgestrel-releasing IUDs have been more variable across study designs (30). These differences have been hypothesised to reflect distinct local mucosal immune effects, whereby copper IUDs may promote a pro-inflammatory cervical environment that facilitates viral clearance, while levonorgestrel-releasing IUDs may exert more immunomodulatory effects on epithelial and cytokine profiles. Although hormonal IUDs were not included in the uChoose trial, these data support the concept that contraceptive-associated effects on HPV outcomes are method-specific and mediated through local mucosal mechanisms, reinforcing the need for comparative studies across systemic, intravaginal, and intrauterine contraceptive modalities.

This study has several limitations. First, the absence of a non-hormonal contraceptive control group precludes direct comparison of HPV outcomes between hormonally exposed and unexposed AGYW. Given the high background risk of HPV acquisition shortly after sexual debut in this population, observed differences in HPV clearance or persistence across study arms should therefore be interpreted as relative effects between hormonal contraceptive methods, rather than as evidence that hormonal contraception per se increases or decreases HPV risk. In addition, because most participants had prior exposure to hormonal contraception at enrolment, the study cannot assess the effects of first-ever hormonal contraceptive initiation; instead, findings reflect comparative effects of switching between hormonal methods in a population with existing contraceptive exposure. Hormonal intrauterine devices were not included in the uChoose trial and therefore could not be evaluated in this analysis. Finally, the relatively short follow-up period of 16 weeks was designed to capture early biologically plausible changes in HPV detection related to contraceptive-induced mucosal alterations, but is insufficient to assess longer-term HPV persistence, progression, or cervical disease outcomes.

The findings suggest that hormonal contraceptives may differentially impact HR-HPV acquisition, persistence, and clearance. The observed benefits of Net-EN in clearing HR-HPV types and the increased acquisition and persistence associated with CCVR underscore the need to explore biological mechanisms underlying these effects. These insights are critical for tailoring contraceptive counseling and HPV prevention strategies, particularly in high-risk populations like AGYW in sub-Saharan Africa. Further research is essential to validate these findings and assess the long-term implications for cervical health and cancer prevention.

ACKNOWLEDGMENTS

We are grateful to all the uChoose study participants and protocol team: Ms Penelope Ngcobo for recruiting and consenting participants, Dr Eve Mendel the study clinician, Sister Janine Nixon the study nurse and Ms Keshani Naidoo for processing the samples, Ms Maria Mwakatima and Zoe Baker for editorial and review support.

AUTHOR CONTRIBUTIONS

Conceived and designed the experiments: J.A.P, R.F.T., H.J., A.L.W. Designed and recruited the study participants: L.G.B., K.G., T.P., and S.B. Processed samples: I.K., C.B., S.J., A.H., and H.G. Performed the experiments: T.F.M., K.P., O.T., and Z.Z.A.M. Analysed the data: R.F.T., and J.A.P. Wrote the manuscript: All authors.

FUNDING

This work was funded by the South African Medical Research Council and the US National Institute of Health (R01 HD083040 for this sub-study to [PIs: Heather Jaspan and Jo-Ann Passmore], and R01AI094586 for the parent study to Linda Gail-Bekker. Merck donated the CCVRs for the study. This HPV sub-study was funded by a grant from the Poliomyelitis Research Foundation to Dr Passmore, and a grant from NRF SARChi Chair to Prof Anna-Lise Williamson.

CONFLICT OF INTEREST

All authors declare no potential conflict of interest.

REFERENCES

1. Newman L, Rowley J, Vander Hoorn S, et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PloS one. 2015;10:e0143304. doi: 10.1371/journal.pone.0143304. PMID: 26646541; PMCID: PMC4672879.

2. Chan CK, Aimagambetova G, Ukybassova T, et al. Human Papillomavirus Infection and Cervical Cancer: Epidemiology, Screening, and Vaccination-Review of Current Perspectives. J Oncol. 2019;10;2019:3257939. doi: 10.1155/2019/3257939. PMID: 31687023; PMCID: PMC6811952.

3. Wei F, Georges D, Man I, et al. Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature. Lancet. 2024;404:435-444; doi: 10.1016/S0140-6736(24)01097-3. PMID: 39097395.

4. Jedy-Agba E, Joko WY, Liu B, et al. Trends in cervical cancer incidence in sub-Saharan Africa. Br J Cancer. 2020;123:148-154. doi: 10.1038/s41416-020-0831-9. PMID: 32336751; PMCID: PMC7341858.

5. Ramogola-Masire D, Luckett R, Dreyer G. Progress and challenges in human papillomavirus and cervical cancer in southern Africa. Curr Opin Infect Dis. 2022;35:49-54. doi: 10.1097/QCO.0000000000000805. PMID: 34873079.

6. Adebamowo, S.N., Adeyemo, A., Adebayo, A. et al. Genome, HLA and polygenic risk score analyses for prevalent and persistent cervical human papillomavirus (HPV) infections. Eur J Hum Genet; 2024;32:708–716. https://doi.org/10.1038/s41431-023-01521-7

7. Hewavisenti RV, Arena J, Ahlenstiel CL, Sasson SC. Human papillomavirus in the setting of immunodeficiency: Pathogenesis and the emergence of next-generation therapies to reduce the high associated cancer risk. Front Immunol. 2023;7;14:1112513. doi: 10.3389/fimmu.2023.1112513. PMID: 36960048; PMCID: PMC10027931.

8. Pino M, Vorsters A, Joura EA, et al. Risk factors for human papillomavirus infection and disease: a targeted literature summary. J Med Virol. 2024; 96:e29420. doi:10.1002/jmv.29420

9. Marks M, Gravitt PE, Gupta SB, et al. Combined oral contraceptive use increases HPV persistence but not new HPV detection in a cohort of women from Thailand. J. Infect. Dis. 2011;204:1505-13. doi: 10.1093/infdis/jir560. PMID: 21964399; PMCID: PMC3222104.

10. Marks M, Gravitt PE, Gupta SB, et al. The association of hormonal contraceptive use and HPV prevalence. Int J Cancer. 2011;128:2962-70. doi: 10.1002/ijc.25628. PMID: 20734390.

11. Guo C, Zhan B, Li MY, et al. Association between oral contraceptives and cervical cancer: A retrospective case-control study based on the National Health and Nutrition Examination Survey. Front Pharmacol. 2024;15:1400667. doi: 10.3389/fphar.2024.1400667. PMID: 39086392; PMCID: PMC11288899.

12. Asthana S, Busa V, Labani S. Oral contraceptives use and risk of cervical cancer-A systematic review & meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2020;247:163-175. doi: 10.1016/j.ejogrb.2020.02.014. Epub 2020 Feb 21. PMID: 32114321.

13. Damayanti S, Budihastuti UR, Murti B. Meta-Analysis: Effects of Hormonal Contraceptive Use and History of Sexually Transmitted Disease on the Risk of Cervical Cancer. J. Maternal Child Health. 2023; 8:711-722. https://doi.org/10.26911/thejmch.2023.08.06.05

14. Mbulawa ZZA, van Schalkwyk C, Hu NC, et al. High human papillomavirus (HPV) prevalence in South African adolescents and young women encourages expanded HPV vaccination campaigns. PLoS One. 2018;13:e0190166. doi: 10.1371/journal.pone.0190166. PMID: 29293566; PMCID: PMC5749739.

15. Gill K, Happel AU, Pidwell T, et al. An open-label, randomized crossover study to evaluate the acceptability and preference for contraceptive options in female adolescents, 15 to 19

years of age in Cape Town, as a proxy for HIV prevention methods (UChoose). J Int AIDS Soc. 2020;23:e25626. doi: 10.1002/jia2.25626. PMID: 33034421; PMCID: PMC7545920.

16. Konstantinus IN, Balle C, Jaumdally SZ, et al. Impact of Hormonal Contraceptives on Cervical T-helper 17 Phenotype and Function in Adolescents: Results from a Randomized, Crossover Study Comparing Long-acting Injectable Norethisterone Oenanthate (NET-EN), Combined Oral Contraceptive Pills, and Combined Contraceptive Vaginal Rings. Clin Infect Dis. 2020 Oct 23;71(7):e76-e87. doi: 10.1093/cid/ciz1063. PMID: 31675420; PMCID: PMC7755094.

17. Balle C, Gupta PM, Tharp GK, et al. Systems Analysis Reveals Contraceptive-Induced Alteration of Cervicovaginal Gene Expression in a Randomized Trial. Front Reprod Health. 2022;4:781687. doi: 10.3389/frph.2022.781687. PMID: 36303659; PMCID: PMC9580795.

18. Balle, C., Konstantinus, I.N., Jaumdally, S.Z. et al. Hormonal contraception alters vaginal microbiota and cytokines in South African adolescents in a randomized trial. Nat Commun 2020;11, 5578. https://doi.org/10.1038/s41467-020-19382-9.

19. Lewis, DA, Müller E, Steele, L, et al. Prevalence and associations of genital ulcer and urethral pathogens in men presenting with genital ulcer syndrome to primary health care clinics in South Africa. Sex. Trans. Dis. 2012;39,880-885. DOI: 10.1097/OLQ.0b013e318269cf90

20. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol. 1991;29:297-301. doi: 10.1128/jcm.29.2.297-301.1991. PMID: 1706728; PMCID: PMC269757.

21. Peters RPH, Garrett N, Chandiwana N, et al. Southern African HIV Clinicians Society 2022 guideline for the management of sexually transmitted infections: Moving towards best practice. South Afr J HIV Med. 2022;23:1450. doi: 10.4102/sajhivmed.v23i1.1450. Erratum in: South Afr J HIV Med. 2022;23):1465. doi: 10.4102/sajhivmed.v23i1.1465. PMID: 36299557; PMCID: PMC9575338.

22. Houlihan CF, de Sanjosé S, Baisley K, et al. Prevalence of human papillomavirus in adolescent girls before reported sexual debut. J Infect Dis. 2014;210:837-45. doi: 10.1093/infdis/jiu202. PMID: 24740630; PMCID: PMC4136803.

23. Smith JS. Prevalence of human papillomavirus infection in adolescent girls before reported sexual debut. J Infect Dis. 2014;210:835-6. doi: 10.1093/infdis/jiu207. PMID: 24740632.

24. Delany-Moretlwe S, Kelley KF, James S, et al. Human Papillomavirus Vaccine Introduction in South Africa: Implementation Lessons From an Evaluation of the National School-Based Vaccination Campaign. Glob Health Sci Pract. 2018;6:425-438. doi: 10.9745/GHSP-D-18-00090. PMID: 30143561; PMCID: PMC6172125.

25. Łaniewski P, Barnes D, Goulder A, et al. Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women. Sci Rep. 2018;8:7593. doi: 10.1038/s41598-018-25879-7. PMID: 29765068; PMCID: PMC5954126.

26. Fernandes JV, Medeiros Fernandes TA, Azevedo JC, et al. Link between chronic inflammation and human papillomavirus-induced carcinogenesis (Review). Oncol Lett. 2015;9:1015-1026. doi: 10.3892/ol.2015.2884. PMID: 25663851; PMCID: PMC4315066.

27. Castellsagué X, Díaz M, Vaccarella S, et al. Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. Lancet Oncol. 2011 Oct;12(11):1023-31. doi: 10.1016/S1470-2045(11)70223-6. Epub 2011 Sep 12. PMID: 21917519.

28. Cortessis VK, Barrett M, Brown Wade N, et al. Intrauterine Device Use and Cervical Cancer Risk: A Systematic Review and Meta-analysis. Obstet Gynecol. 2017;130:1226-1236. doi: 10.1097/AOG.0000000000002307. PMID: 29112647.

29. Averbach SH, Ma Y, Smith-McCune K, et al. The effect of intrauterine devices on acquisition and clearance of human papillomavirus. Am J Obstet Gynecol. 2017;216:386.e1-386.e5. doi: 10.1016/j.ajog.2016.11.1053. PMID: 27986460; PMCID: PMC5406303.
30. Jans L, Brynhildsen J, Cherif E, et al. Prevalence of high-risk HPV and cervical dysplasia in IUD users and controls: a cross-sectional study. Eur J Contracept Reprod Health Care. 2024;29:109-114. doi: 10.1080/13625187.2024.2340521. PMID: 38666336.

Table 1. Baseline demographic, behavioural, and clinical characteristics of adolescent girls and young women enrolled in the uChoose HPV sub-study

Contraceptive arm	All	Net-EN[a]	COCP	CCVR[b]
n	98/130 (75.4%)	44/98 (44.9%)	24/98 (24.5%)	25/98 (25.5%)
Age (years)*	17.0 (16.0 – 18.0)	17.0 (16.0 – 18.0)	16.0 (16.0 – 18.0)	17.0 (16.0 – 18.5)
Body mass index (kg/m^2)*	25.1 (21.5 – 29.1)	25.8 (22.6 – 29.8)	25.5 (20.7 – 30.5)	24.9 (21.1 – 26.5)
Age of sexual debut (years)*	13 (12.0 – 14.0)	13 (12.0 – 14.0)	14 (12.0 – 15.0)	13 (12.0 – 15.0)
Condom use during last sex	55/98 (56.1%)	24/44 (54.5%)	14/24 (58.3%)	15/25 (60.0%)
>1 sex partners in past year	21/98 (21.4%)	10 (27.8%)	5 (20.8%)	6 (24.0%)
New partners in past year	28/98 (28.6%)	10 (22.7%)	7 (29.2%)	10 (40.0%)
Prior hormonal contraceptive use:				
Never	1/98 (1.0%)	1 (2.3%)	0 (0.0%)	0 (0.0%)
Not currently	21/98 (21.4%)	9 (20.5%)	7 (29.2%)	4 (16.0%)
DMPA	9/98 (9.2%)	4 (9.1%)	4 (16.7%)	1 (4.0%)
Implanon	2/98 (2.0%)	1(2.3%)	0 (0.0%)	1 (4.0%)
COCPs	3/98 (3.1%)	2 (4.5%)	0 (0.0%)	1 (4.0%)
Net-EN	62/98 (63.3%)	27 (61.4%)	13 (54.2%)	18 (72.0%)
Vaginal pH*	4.9 (4.4 – 5.3)	5.0 (4.7 – 5.3)	4.7 (4.4 – 5.0)	4.7 (4.4 – 5.3)
Bacterial vaginosis:				
Negative (Nugent 0 – 3)	46/98 (46.9%)	18/44 (40.9%)	12/24 (50.0%)	13/25 (52.0%)
Intermediate (Nugent 4 – 6)	10/98 (10.2%)	6/44 (13.6%)	1/24 (4.2%)	2/25 (8.0%)
Positive (Nugent 7 – 10)	42/98 (42.9%)	20/44 (45.5%)	10/24 (41.7%)	11/25 (44.0%)
STIs:				
Chlamydia trachomatis	31/98 (31.6%)	12/44 (27.3%)	9/24 (37.5%)	9/25 (36.0%)
Neisseria gonorrhoeae	12/98 (12.2%)	5/44 (11.4%)	3/24 (12.5%)	3/25 (12.0%)
Trachomatis vaginalis	8/98 (8.2%)	5/44 (11.4%)	1/24 (4.2%)	2/25 (8.0%)
Mycoplasma genitalium	3/98 (3.1%)	2/44 (4.6%)	1/24 (4.2%)	0/25 (0.0%)

*Median and 25th and 75th percentile; n: sample size
[a]No record available for age of sexual debut (n=3), condom use during last sex (n=8), numbers of sexual partners (n=8), new partners (n=9) and endogenous hormone levels (n=2) and n=1
[b]No data available for endogenous hormone levels (n=1)
Abbreviations: COCP, combined oral contraceptive pill; CCVR, combined contraceptive vaginal ring; Net-EN, norethisterone enanthate; DMPA, depot medroxyprogesterone acetate.

13   Table 2. HPV prevalence in participants with paired baseline and week-16 samples

Outcome	Time Point	Contraceptive Arm			Between arms P-value[a] (vs Net-EN at each time point)		Within-arm change (Baseline vs 16 weeks): Odds Ratio (95% CI); P-value[b]		
		Net-EN	COCP	CCVR	COCP	CCVR	Net-EN	COCP	CCVR
Any HPV	Baseline	35/36 (97.2%)	22/25 (88.0%)	25/26 (96.2%)	0.1	1.0			
	16-weeks	31/36 (86.1%)	22/25 (88.0%)	24/26 (92.3%)	1.0	0.7	-[c]; 0.07	-[c]; 1.0	-[c]; 0.5
HR-HPV	Baseline	29/36 (80.6%)	18/25 (72.0%)	21/26 (80.8%)	0.5	1.0			
	16-weeks	24/36 (66.7%)	14/25 (56.0%)	20/26 (76.9%)	0.8	0.4	0.2 (0.004-1.8); 0.2	3.0 (0.2-157.5); 0.6	1.0 (0.01-78.5); 0.5
Multiple HPV	Baseline	27/36 (75.0%)	20/25 (80.0%)	19/26 (73.1%)	0.3	0.4			
	16-weeks	21/36 (58.3%)	16/25 (64.0%)	19/26 (73.1%)	0.3	0.1	0.3 (0.3-1.9); 0.3	0.3 (0.3-1.9); 0.3	0.8 (0.2-3.7); 1.0

[a]Between-arm comparisons at each time point were assessed using Fisher's exact test, with Net-EN as the reference group.

[b]Within-arm changes from baseline to 16 weeks were assessed using McNemar's test for paired binary data.

[c]Odds ratios could not be calculated because one or more discordant cells contained zero values.

FIGURE LEGENDS

Figure 1. Dynamics of HPV Infections Across Contraceptive Methods.

Percentage of AGYW with cleared, persistent, and newly acquired HPV infections, based on paired data

between baseline and week 16 visits. Results are stratified by hormonal contraceptive methods: CCVR

(n=26), COCPs (n=25), and Net-EN (n=36). Color coding reflects infection categories: pink for any HPV,

orange for HR HPV, darker blue for LR-HPV, and lighter blue for multiple HPVs.

Figure 2. HPV Genotype Distribution Across Contraceptive Arms.

Stacked bars show the prevalence of HR HPV types (including HPV-66 and -68 which were

previously classified as HR) that were newly acquired between 0 and 16 weeks (left panel),

cleared (middle panel), or persisted (right panel), stratified by genotype and contraceptive

method, based on paired baseline and week 16 samples only. Panels represent data for Net-EN

(n=36), COCPs (n=25), and CCVR (n=26), based on paired samples between baseline and week

16 visits.

Supplemental Figure 1. Study design overview

Study design for the open-label, randomized crossover uChoose trial conducted among

adolescent girls and young women (AGYW). Participants were randomized to one of three

hormonal contraceptive methods: combined oral contraceptive pills (COCPs), injectable

norethisterone enanthate (Net-EN), or the combined contraceptive vaginal ring (CCVR). In the

parent uChoose trial, participants used an assigned hormonal contraceptive method for 16 weeks

before crossing over to an alternative method, with no washout period between interventions; the

primary outcomes of the parent trial were acceptability, feasibility, and adherence. The present

HPV sub-study was restricted to samples collected at baseline and after the initial 16-week

randomized exposure period, prior to crossover, and evaluated HPV prevalence and genotype

dynamics. Accordingly, analyses presented here reflect comparisons across contraceptive

methods during the first exposure period only. Numbers (n) indicate the number of participants

with available and typeable HPV genotyping data for the specific outcome and time point

shown; variation in n across contraceptive arms reflects missing or insufficient samples for

genotyping at specific visits.

Supplementary Figure 2. Distribution of HPV genotypes at baseline and 16 weeks by

randomized contraceptive arm.

Distribution of HPV genotypes among adolescent girls and young women (AGYW) at baseline

and at 16 weeks, using all available samples at each time point. Each bar graph represents the

prevalence of a specific HPV genotype. Light colours indicate low-risk HPV (LR-HPV) types,

while dark colours represent high-risk HPV (HR-HPV) types. Genotypes no longer classified as

high-risk by the International Agency for Research on Cancer (IARC) are shown in green italics.

Genotypes targeted by the bivalent (HPV-16, -18), quadrivalent (HPV-6, -11, -16, -18), and

nonavalent (HPV-6, -11, -16, -18, -31, -33, -45, -52, -58) vaccines are highlighted in bold.

Although the parent uChoose trial employed a crossover design, the present HPV sub-study

includes only data from the first randomized exposure period (baseline to 16 weeks), prior to

crossover.

Figure 1

Figure 2